Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ionis Reaches Milestone in Biogen Neurology Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ionis Reaches Milestone in Biogen Neurology Pact

Paid $10 million for advancing a new program in its neurology collaboration

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ionis Pharmaceuticals has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. Ionis will continue to evaluate this newest target with the goal of advancing this program into development.

“We continue to make substantial progress in validating new targets and developing new drugs for neurological diseases using our antisense technology. Spinraza, the first drug to come out of our neurology collaboration with Biogen, exemplifies the potential of our antisense technology in the neurological disease space. To date, our collaboration with Biogen has generated a combined total of nearly $650 million,” said B. Lynne Parshall, chief operating officer, Ionis Pharmaceuticals. “As we continue to advance our neurological disease pipeline, we look forward to bringing additional important medicines to patients suffering from neurodegenerative diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics